Literature DB >> 17205602

Differential radioactive quantification of protein abundance ratios between benign and malignant prostate tissues: cancer association of annexin A3.

Wojciech Wozny1, Klaus Schroer, Gerhard P Schwall, Slobodan Poznanović, Werner Stegmann, Klaus Dietz, Hermann Rogatsch, Georg Schaefer, Heidi Huebl, Helmut Klocker, André Schrattenholz, Michael A Cahill.   

Abstract

A differential quantitative protein expression study, comparing matched prostate cancerous and benign tissues from 31 patients, revealed proteins newly associated with prostate cancer. Average effects for 17 proteins whose abundance was significantly different (p<0.01) across patients ranged from 1.5- to 6.1-fold, and included a number of known cancer markers. The most differentially abundant proteins between cancer and benign samples were isopeptidase T, serum amyloid P (SAP), annexin A3 (ANXA3) and mitochondrial enoyl coenzyme-A hydratase. SAP is restricted to stroma in healthy tissue, and the lower abundance in tumours may be explained by the reduced stromal content. ANXA3 is present in healthy epithelial cells, exhibits strong staining in precancerous prostatic intraepithelial neoplasia, and is relatively less abundant in individual tumour cells of increasing Gleason pattern (GP), despite exhibiting higher overall tissue abundance in tumours. ANXA3 staining was predominantly cytoplasmic, yet nuclear localization was also observed. Strongly staining single cells, possibly phagocytes, were interspersed in highly dedifferentiated GP5 tumour areas among tumour cells without measurable ANXA3. Local recurrent androgen ablation therapy-resistant tumours exhibit heterogenous low levels of ANXA3 staining. Results are discussed focussing on the potential implications for tumour tissues.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17205602     DOI: 10.1002/pmic.200600646

Source DB:  PubMed          Journal:  Proteomics        ISSN: 1615-9853            Impact factor:   3.984


  12 in total

1.  Hydrophobic protein in colorectal cancer in relation to tumor stages and grades.

Authors:  Lay-Chin Yeoh; Chee-Keat Loh; Boon-Hui Gooi; Manjit Singh; Lay-Harn Gam
Journal:  World J Gastroenterol       Date:  2010-06-14       Impact factor: 5.742

2.  [Identification and validation of clinically relevant molecular alterations in prostate cancer].

Authors:  T Schlomm; H Sültmann; J Köllermann
Journal:  Urologe A       Date:  2008-09       Impact factor: 0.639

3.  [Identification and validation of clinically relevant molecular alterations in prostate cancer].

Authors:  T Schlomm; H Sültmann; J Köllermann
Journal:  Pathologe       Date:  2009-03       Impact factor: 1.011

4.  2D-difference gel electrophoretic proteomic analysis of a cell culture model of alveolar rhabdomyosarcoma.

Authors:  Joseph G Pressey; Christine S Pressey; Gloria Robinson; Richie Herring; Landon Wilson; David R Kelly; Helen Kim
Journal:  J Proteome Res       Date:  2011-01-10       Impact factor: 4.466

5.  Primary cell cultures from human renal cortex and renal-cell carcinoma evidence a differential expression of two spliced isoforms of Annexin A3.

Authors:  Cristina Bianchi; Silvia Bombelli; Francesca Raimondo; Barbara Torsello; Valentina Angeloni; Stefano Ferrero; Vitalba Di Stefano; Clizia Chinello; Ingrid Cifola; Lara Invernizzi; Paolo Brambilla; Fulvio Magni; Marina Pitto; Gianpaolo Zanetti; Paolo Mocarelli; Roberto A Perego
Journal:  Am J Pathol       Date:  2010-02-18       Impact factor: 4.307

6.  Combined analysis of transcriptome and proteome data as a tool for the identification of candidate biomarkers in renal cell carcinoma.

Authors:  Barbara Seliger; Sven P Dressler; Ena Wang; Roland Kellner; Christian V Recktenwald; Friedrich Lottspeich; Francesco M Marincola; Maja Baumgärtner; Derek Atkins; Rudolf Lichtenfels
Journal:  Proteomics       Date:  2009-03       Impact factor: 3.984

7.  Annexin A3 is a mammary marker and a potential neoplastic breast cell therapeutic target.

Authors:  Bashar Zeidan; Thomas R Jackson; Samantha E T Larkin; Ramsey I Cutress; Gary R Coulton; Margaret Ashton-Key; Nick Murray; Graham Packham; Vassilis Gorgoulis; Spiros D Garbis; Paul A Townsend
Journal:  Oncotarget       Date:  2015-08-28

8.  Secretion of annexin A3 from ovarian cancer cells and its association with platinum resistance in ovarian cancer patients.

Authors:  Jie Yin; Xuedong Yan; Xin Yao; Yongli Zhang; Ying Shan; Ning Mao; Yili Yang; Lingya Pan
Journal:  J Cell Mol Med       Date:  2012-02       Impact factor: 5.310

9.  Characterisation and protein expression profiling of annexins in colorectal cancer.

Authors:  R Duncan; B Carpenter; L C Main; C Telfer; G I Murray
Journal:  Br J Cancer       Date:  2007-12-11       Impact factor: 7.640

Review 10.  The present and future of prostate cancer urine biomarkers.

Authors:  Marina Rigau; Mireia Olivan; Marta Garcia; Tamara Sequeiros; Melania Montes; Eva Colás; Marta Llauradó; Jacques Planas; Inés de Torres; Juan Morote; Colin Cooper; Jaume Reventós; Jeremy Clark; Andreas Doll
Journal:  Int J Mol Sci       Date:  2013-06-17       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.